ABSK-091
- Generic Name
- ABSK-091
- Drug Type
- Small Molecule
- Chemical Formula
- C26H33N5O3
- CAS Number
- 1035270-39-3
Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer
Phase 2
Terminated
- Conditions
- Gastro-oesophageal Junction CancerGastric Cancer
- Interventions
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 960
- Registration Number
- NCT01457846
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient
- First Posted Date
- 2010-10-01
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT01213160
- Locations
- 🇯🇵
Research Site, Sapporo-shi, Japan
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
Phase 1
Completed
- Conditions
- FGFR Inhibition, Pharmacokinetics, BiomarkersER+ Breast Cancer
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 127
- Registration Number
- NCT01202591
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours
- First Posted Date
- 2009-09-17
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 95
- Registration Number
- NCT00979134
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath